Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Senti Biosciences Holdings's Enterprise Value for the quarter that ended in Jun. 2026 was $48.02 Mil.
Senti Biosciences Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senti Biosciences Holdings EV-to-EBIT Related Terms
Senti Biosciences Holdings EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Senti Biosciences Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Senti Biosciences Holdings EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Senti Biosciences Holdings's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Senti Biosciences Holdings's EV-to-EBIT falls into.
Senti Biosciences Holdings's current Enterprise Value is $27.15 Mil.
Senti Biosciences Holdings's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-56.52 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Senti Biosciences Holdings (SNTI) has a EV-to-EBIT of -0.48 as of Aug. 18, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Senti Biosciences Holdings and its competitors. According to the industry distribution chart, Senti Biosciences Holdings ranks #999999 out of 370 companies in the Biotechnology industry.
Is Senti Biosciences Holdings' EV-to-EBIT too high?
Senti Biosciences Holdings' current EV-to-EBIT is -0.48. Based on the distribution chart, Senti Biosciences Holdings ranks #999999 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Senti Biosciences Holdings has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Senti Biosciences Holdings' EV-to-EBIT compare to ZEOX and BCDA?
According to the Biotechnology industry distribution chart, Senti Biosciences Holdings ranks #999999 out of 370 companies for EV-to-EBIT. This places Senti Biosciences Holdings in the lower half of its industry. The industry median EV-to-EBIT is 16.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 16.12, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Senti Biosciences Holdings and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 16.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Senti Biosciences Holdings's current EV-to-EBIT is -0.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Senti Biosciences Holdings stock overvalued right now?
Senti Biosciences Holdings (SNTI) has a current EV-to-EBIT of -0.48. The current EV-to-EBIT is -0.48. Senti Biosciences Holdings' overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Senti Biosciences Holdings (SNTI), the current EV-to-EBIT is -0.48 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
25GF Score
Get the complete analysis for SNTI
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SNTI has been successfully added to your 
